Post-transplant lymphoproliferative disorders in children: The role of chemotherapy in the era of rituximab

Pediatric Transplantation

Volumn 14, Issue 1, 2010, Pages 61-66

  Gallego, S ^a   Llort, A ^a   Gros, L ^a   Sanchez De Toledo Jr , J ^a   Bueno, J ^a   Moreno, A ^a   Nieto, J ^a   Sanchez De Toledo, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Chemotherapy; Children; Post transplant lymphoproliferative disorders; Rituximab

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; EVENT FREE SURVIVAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE CYCLE TREATMENT; ONSET AGE; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PEDIATRIC SURGERY; SEPTIC SHOCK;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LYMPHOPROLIFERATIVE DISORDERS; MALE; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN; TREATMENT OUTCOME;

EID: 74349097959     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2009.01181.x     Document Type: Article

References (30)

1. Ajithkumar TV, Parkinson CA, Butler A, Hatcher HM. Management of solid tumours in organ-transplant recipients. Lancet Oncol 2007 : 8 : 921 932.
2. Walker RC, Marshall WF, Stricker JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995 : 20 : 1346 1353.
3. Quintini C, Kato T, Gaynor JJ, et al. Analysis of risk factors for the development of posttransplant lymphoproliferative disorder among 119 children who received primary intestinal transplants at a single center. Transplant Proc 2006 : 38 : 1755 1758.
4. Lay YC, Ni YH, Jou ST, et al. Post-transplantation lymphoproliferative disorders localizing to the gastrointestinal tract after liver transplantation: Report of five pediatric cases. Pediatr Transplant 2006 : 10 : 390 394.
5. Katz BZ, Pahl E, Crawford SE, et al. Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort. Pediatr Transplant 2007 : 11 : 58 65.
6. D'alesandro AM, Knechtle SJ, Chin LT, et al. Liver transplantation in pediatric patients: Twenty years of experience at the University of Wisconsin. Pediatr Transplant 2007 : 11 : 661 670.
7. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003 : 76 : 984 988.
8. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: Summary of society for hematopathology workshop. Semin Diagn Pathol 1997 : 14 : 8 14.
9. Everly MJ, Bloom RD, Tsai DE, Trofe J. Posttransplant lymphoproliferative disorder. Ann Pharmacother 2007 : 41 : 1850 1858.
10. Lacasce AS. Post-transplant lymphoproliferative disorders. Oncologist 2006 : 11 : 674 680.
11. Lee JJ, Lam MS, Rosenberg A. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation. Ann Pharmacother 2007 : 41 : 1648 1659.
12. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: Dissimilarities from lymphomas in adults. Semin Oncol 1980 : 7 : 332 339.
13. Patte C, Auperin A, Michon J, et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001 : 97 : 3370 3379.
14. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1984 : 1 : 583 587.
15. Dror Y, Greenberg M, Taylor G, et al. Lymphoproliferative disorders after organ transplantation in children. Transplantation 1999 : 67 : 990 998.
16. Boratynska M, Watorek D, Smolska D, et al. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc 2007 : 39 : 2736 2739.
17. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with TOR inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005 : 80 : 883 889.
18. Ganne V, Siddiqi N, Kamaplath B, et al. Humanized anti-CD20 monoclonal antibody (rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 2003 : 17 : 417 422.
19. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005 : 5 : 2901 2906.
20. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006 : 107 : 3053 3057.
21. Garrett TJ, Chadburn A, Barr ML, et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin- vincristine-prednisone chemotherapy. Cancer 1993 : 72 : 2782 2785.
22. Balfour IC, Wall D, Luisiri A, et al. Cyclophosphamide-prednisone for combination immunosuppression and therapy of lymphoproliferative disease. J Heart Lung Transplant 1999 : 18 : 492 495.
23. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006 : 6 : 569 576.
24. Trappe R, Riess H, Babe N, et al. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation 2007 : 83 : 912 918.
25. Gallego-Melcon S, Sanchez De Toledo J, Martinez V, et al. Non-Hodgkin lymphoma after liver transplantation: Response to chemotherapy. Med Pediatr Oncol 1996 : 27 : 156 159.
26. Williams KM, Higman MA, Chen AR, et al. Successful treatment of a child with late onset T-cell post-transplant lymphoproliferative disorder/lymphoma. Pediatr Blood Cancer 2008 : 50 : 667 670.
27. Forns M, Javier G, Estella J, et al. Results of the SHOP LNHB98 (LMB89) trial in pediatric patients with B-cell non-Hodgkin's lymphoma. Med Clin (Barc) 2007 : 128 : 641 646.
28. Giulino LB, Bussel JB, Neufeld EJ, et al. Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr 2007 : 150 : 338 344.
29. Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplant lymphoproliferative disorders. J Clin Oncol 2005 : 23 : 7574 7582.
30. Maecker B, Jack T, Zimmermann M, et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007 : 25 : 4902 4908.